Concepedia

Narimon Honarpour

NH

Statistics

Publications

34

Citations

5.8K

H-Index

26

Active since

2000

Affiliations

Amgen (United States)(Current)

Brigham and Women's Hospital

Thrombolysis in Myocardial Infarction Study Group

Imperial College London

National Health and Medical Research Council

Narimon Honarpour is an author at Amgen (United States) specializing in pharmacology, clinical pharmacology, and pharmacotherapy.

Publications per year

2000–2025

34

Publications

34

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Narimon Honarpour, Dirk Blom et al. · The Lancet · 2014 · 727 citations

, , +14

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

John R. Teerlink, Rafael Díaz, G. Michael Felker et al. · New England Journal of Medicine · 2020 · 644 citations · Full text

, , +15

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 596 citations · Full text

, , +16

Cognitive Function in a Randomized Trial of Evolocumab

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · New England Journal of Medicine · 2017 · 482 citations · Full text

, , +16

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Evan A. Stein, Narimon Honarpour, Scott M. Wasserman et al. · Circulation · 2013 · 330 citations · Full text

, , +17

1–5 of 34